Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
AIMS/HYPOTHESIS: The aim of this study was to determine the pattern of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin on cardiovascular events in patients with type 2 diabetes and no prior history of cardiovascular disease (CVD). MATERIALS AND METHODS: A po...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797091438253572096 |
|---|---|
| author | Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Thomason, M Fuller, J |
| author_facet | Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Thomason, M Fuller, J |
| author_sort | Colhoun, H |
| collection | OXFORD |
| description | AIMS/HYPOTHESIS: The aim of this study was to determine the pattern of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin on cardiovascular events in patients with type 2 diabetes and no prior history of cardiovascular disease (CVD). MATERIALS AND METHODS: A post hoc analysis of data from the Collaborative Atorvastatin Diabetes Study (CARDS), a randomised, placebo-controlled trial of 2,838 patients with type 2 diabetes, was performed. Patients received atorvastatin (10 mg daily) or placebo and were evaluated for cardiovascular and other outcomes over a median follow-up period of 3.9 years. Cox proportional hazards modelling was carried out, and the hazard ratios calculated for various times after randomisation to treatment were investigated. RESULTS: A reduction in the primary endpoint of major CVD events was apparent and statistically significant as soon as 18 months after treatment initiation. The effect of atorvastatin on CHD events was apparent by 6 months, and at 1 year was similar to the 37% relative risk reduction observed at trial closure. CONCLUSIONS/INTERPRETATION: Atorvastatin alters the pathogenesis of CVD rapidly, such that the effect on cardiovascular events is apparent within months of initiation of therapy. |
| first_indexed | 2024-03-07T03:33:04Z |
| format | Journal article |
| id | oxford-uuid:bb5df2da-6b68-400f-a298-ff816a9b8467 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:33:04Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:bb5df2da-6b68-400f-a298-ff816a9b84672022-03-27T05:16:25ZRapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bb5df2da-6b68-400f-a298-ff816a9b8467EnglishSymplectic Elements at Oxford2005Colhoun, HBetteridge, DDurrington, PHitman, GNeil, HLivingstone, SThomason, MFuller, J AIMS/HYPOTHESIS: The aim of this study was to determine the pattern of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin on cardiovascular events in patients with type 2 diabetes and no prior history of cardiovascular disease (CVD). MATERIALS AND METHODS: A post hoc analysis of data from the Collaborative Atorvastatin Diabetes Study (CARDS), a randomised, placebo-controlled trial of 2,838 patients with type 2 diabetes, was performed. Patients received atorvastatin (10 mg daily) or placebo and were evaluated for cardiovascular and other outcomes over a median follow-up period of 3.9 years. Cox proportional hazards modelling was carried out, and the hazard ratios calculated for various times after randomisation to treatment were investigated. RESULTS: A reduction in the primary endpoint of major CVD events was apparent and statistically significant as soon as 18 months after treatment initiation. The effect of atorvastatin on CHD events was apparent by 6 months, and at 1 year was similar to the 37% relative risk reduction observed at trial closure. CONCLUSIONS/INTERPRETATION: Atorvastatin alters the pathogenesis of CVD rapidly, such that the effect on cardiovascular events is apparent within months of initiation of therapy. |
| spellingShingle | Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Thomason, M Fuller, J Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title_full | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title_fullStr | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title_full_unstemmed | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title_short | Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). |
| title_sort | rapid emergence of effect of atorvastatin on cardiovascular outcomes in the collaborative atorvastatin diabetes study cards |
| work_keys_str_mv | AT colhounh rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT betteridged rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT durringtonp rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT hitmang rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT neilh rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT livingstones rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT thomasonm rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards AT fullerj rapidemergenceofeffectofatorvastatinoncardiovascularoutcomesinthecollaborativeatorvastatindiabetesstudycards |